To remain competitive, cost estimates for these new drug approvals are expected to be between $10,000 and $18,000 annually at wholesale acquisition cost
Being overweight or obese poses many health risks
The metabolic analysis demonstrated strong enzymatic activity with a high release of amino acids and beneficial short-chain fatty acids (SCFAs)
"Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine, 2022, 387(3), 205-216
In practice, people losing weight on GLP-1s rely on the drug to create and maintain a calorie deficit
You have a BMI between 30-34.99 and have at least one of these conditions: Diastolic heart failure (also called heart failure with preserved ejection fraction) Uncontrolled high blood pressure (also called hypertension) Chronic kidney disease at stage 3a or higher Prediabetes A previous heart attack (also called myocardial infarction) or stroke Blocked arteries in your legs or arms (also called peripheral artery disease) with symptoms You have a BMI between 27-29.99 and have at least one of these conditions: Prediabetes A previous heart attack (also called myocardial infarction) or stroke Blocked arteries in your legs or arms (also called peripheral artery disease) with symptoms Beneficiaries who receive GLP-1 medications through existing Medicare prescription drug coverage or are eligible through their existing Medicare Part D program arent eligible.